In prostate cancer, TP53 mutations have been demonstrated to be closely associated with high-grade differentiation, disease progression, and therapeutic resistance, while in chronic lymphocytic leukemia (CLL), TP53 aberrations are well-established molecular markers of poor prognosis (17, 18). This evidence concerns the gene TP53 and Familial prostate cancer.